Showing 2121-2130 of 2494 results for "".
- Alcon Showcases Five Innovations Across Multiple Specialty Areas at ASCRS 2025https://modernod.com/news/alcon-showcases-five-innovations-across-multiple-specialty-areas-at-ascrs-2025/2482744/Alcon announced its lineup of new product offerings at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28, in Los Angeles. This year’s event will feature Alcon’s most recent product introductions across specialty areas rangi
- Staar Surgical Announces Restructure of Leadershiphttps://modernod.com/news/staar-surgical-announces-restructure-of-leadership/2482705/Staar Surgical announced a series of changes to their leadership structure. These changes come in an effort to better address marketing needs, according to Staar. Warren Foust, Chief Operating Officer, has been promoted to the newly created role of Preside
- Harrow Launches 'Vevye Access for All' to Reduce Patient Barriers for Dry Eye Disease Treatmenthttps://modernod.com/news/harrow-launches-vevye-access-for-all-reducing-patient-barriers-for-dry-eye-disease-treatment/2482703/Harrow announced 'Vevye Access For All' – a new initiative that aims to reduce patient barriers to dry eye disease treatment. Harrow partnered with specialty pharmacy PhilRx to offer Vevye (cyclosporine ophthalmic solution) 0.1% for eligible patients at $59 a bottle. The g
- Alcon Announces US Launch of Systane PRO PF for Dry Eye Reliefhttps://modernod.com/news/alcon-announces-us-launch-of-systane-pro-pf-for-dry-eye-relief/2482678/Alcon has launched Systane PRO Preservative-Free (PF) in the US, the latest addition to its over-the-counter dry eye portfolio. According to Alcon, Systane PRO PF is the longest-lasting eye drop in the Systane lineup, offering a tr
- Oculus Launches Myopia Software Package on the Pentacam AXL Wavehttps://modernod.com/news/oculus-launches-myopia-software-package-on-the-pentacam-axl-wave/2482670/Oculus is launching the Myopia Software Package on the Pentacam AXL Wave. The new software is designed to offer optometrists improved accuracy, ease, and safety in their myopia management, comprehensive screening, and ortho-k fitting with one device. The Pentacam AXL
- Hoya Vision Care Expands MiYOSMART Power Range for High Myopia Treatment in Childrenhttps://modernod.com/news/hoya-vision-care-expands-miyosmart-power-range-for-high-myopia-treatment-in-children/2482630/Hoya Vision Care announced the launch of an extended power range for its MiYOSMART spectacle lenses, offering a new solution for children suffering from high myopia. Designed specifically to address the needs of high myopic patients, the new lenses feature a broader range of prescriptions, slimme
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the
- Prevent Blindness Provides Free Glaucoma Resources to Patients, Care Partners, and Professionalshttps://modernod.com/news/prevent-blindness-provides-free-glaucoma-resources-to-patients-care-partners-and-professionals/2482593/As part of January’s National Glaucoma Awareness Month, the non-profit Prevent Blindness is offering free educational resources to patients, care partners, and professionals. The resources include downloadable
- Ophthalmic Industry Veteran Scott Hunter Passes Awayhttps://modernod.com/news/ophthalmic-industry-veteran-scott-hunter-passes-away/2482564/Longtime ophthalmic industry leader Scott Hunter passed away on December 3, Neurotech announced. Mr. Hunter was the Chief Commercial Officer of Neurotech, a position he held since January 2023. “The entire Neurotech family mourns this loss. On behalf of the Board of Directors, man
- FDA Accepts Aldeyra's NDA for Reproxalap in Dry Eye Disease; Expands Partnership with AbbViehttps://modernod.com/news/fda-accepts-aldeyras-nda-for-reproxalap-in-dry-eye-disease/2482547/Aldeyra Therapeutics announced that the FDA has officially accepted for review the resubmitted new drug application (NDA) for its topical ocular therapy, reproxalap, aimed at treating the signs and symptoms of dry eye disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target d